Caribou Biosciences

Caribou Biosciences is a clinical-stage CRISPR genome-editing company founded by Nobel laureate Jennifer Doudna to develop allogeneic cellular therapies for malignancies. The company utilizes proprietary chRDNA technology, featuring hybrid RNA and DNA guides that provide high specificity and reduce off-target genomic cleavage during Cas editing. Through multiplex gene editing, Caribou Biosciences engineers off-the-shelf CAR-T cell therapies that target hematologic cancers and autoimmune conditions.